February 11, 2014 / 6:05 PM / 4 years ago

FDA panel says data does not support lower heart risk of naproxen

Feb 11 (Reuters) - An advisory panel to the U.S. Food and Drug Administration voted on Tuesday that there is not enough evidence to show conclusively that the painkiller naproxen carries a lower cardiac risk than other popular products.

The panel voted 16-9 that a retrospective review of clinical data does not prove that naproxen, a drug contained in the prescription product Naprosyn and over-the-counter Aleve, carries less cardiovascular risk than rival products such as ibuprofen.

Naprosyn is made by Roche Holding, and Aleve is a product of Bayer AG.

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below